36.56
price down icon0.54%   -0.20
after-market Dopo l'orario di chiusura: 36.56
loading
Precedente Chiudi:
$36.76
Aprire:
$36.29
Volume 24 ore:
1.33M
Relative Volume:
0.89
Capitalizzazione di mercato:
$6.78B
Reddito:
$29.52M
Utile/perdita netta:
$-567.06M
Rapporto P/E:
-9.9891
EPS:
-3.66
Flusso di cassa netto:
$-551.11M
1 W Prestazione:
+0.25%
1M Prestazione:
-4.07%
6M Prestazione:
-23.43%
1 anno Prestazione:
+4.70%
Intervallo 1D:
Value
$36.01
$37.89
Intervallo di 1 settimana:
Value
$35.40
$37.89
Portata 52W:
Value
$29.17
$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name
Nome
Revolution Medicines Inc
Name
Telefono
415-766-3638
Name
Indirizzo
700 SAGINAW DR, REDWOOD CITY, CA
Name
Dipendente
534
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
RVMD's Discussions on Twitter

Confronta RVMD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RVMD
Revolution Medicines Inc
36.56 6.78B 29.52M -567.06M -551.11M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-16 Reiterato Needham Buy
2024-07-12 Iniziato Barclays Overweight
2024-07-08 Iniziato Jefferies Buy
2024-04-12 Reiterato Needham Buy
2024-04-10 Aggiornamento Raymond James Outperform → Strong Buy
2024-03-11 Iniziato Piper Sandler Overweight
2024-01-05 Aggiornamento BofA Securities Neutral → Buy
2024-01-04 Iniziato Wedbush Outperform
2023-11-16 Iniziato Raymond James Outperform
2023-02-28 Aggiornamento JP Morgan Neutral → Overweight
2022-12-14 Iniziato Needham Buy
2022-10-21 Iniziato Oppenheimer Outperform
2022-05-20 Iniziato BofA Securities Neutral
2022-03-01 Aggiornamento Stifel Hold → Buy
2021-09-23 Iniziato Stifel Hold
2021-08-12 Downgrade Goldman Buy → Neutral
2021-05-18 Iniziato Goldman Buy
2020-05-21 Iniziato H.C. Wainwright Buy
2020-03-09 Iniziato Cowen Outperform
2020-03-09 Iniziato Guggenheim Buy
2020-03-09 Iniziato JP Morgan Neutral
Mostra tutto

Revolution Medicines Inc Borsa (RVMD) Ultime notizie

pulisher
Apr 20, 2025

Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire

Apr 20, 2025
pulisher
Apr 09, 2025

Revolution Medicines at Stifel Forum: RAS-Driven Cancer Insights By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 07, 2025

Revolution Medicines stock hits 52-week low at $30.02 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Revolution Medicines at Needham Conference: Progress in Cancer Treatment - Investing.com Australia

Apr 07, 2025
pulisher
Apr 07, 2025

Revolution Medicines at Needham Conference: Progress in Cancer Treatment By Investing.com - Investing.com Canada

Apr 07, 2025
pulisher
Apr 07, 2025

Revolution Medicines stock hits 52-week low at $30.02 By Investing.com - Investing.com India

Apr 07, 2025
pulisher
Apr 02, 2025

When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 01, 2025

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Apr 01, 2025
pulisher
Apr 01, 2025

Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan

Mar 31, 2025
pulisher
Mar 30, 2025

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey

Mar 30, 2025
pulisher
Mar 26, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Mar 26, 2025
pulisher
Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa

Mar 24, 2025
pulisher
Mar 24, 2025

Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com

Mar 24, 2025
pulisher
Mar 20, 2025

Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 19, 2025

Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines Executives Sell Shares - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Revolution Medicines COO Margaret Horn sells $119,385 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 15, 2025

Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register

Mar 15, 2025
pulisher
Mar 13, 2025

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com

Mar 13, 2025
pulisher
Mar 13, 2025

Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada

Mar 13, 2025
pulisher
Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

(RVMD) Long Term Investment Analysis - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 11, 2025

Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK

Mar 11, 2025
pulisher
Mar 08, 2025

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers - ACS Publications

Mar 08, 2025
pulisher
Mar 06, 2025

Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey

Mar 06, 2025
pulisher
Mar 04, 2025

10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey

Mar 04, 2025
pulisher
Mar 04, 2025

Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance

Mar 03, 2025
pulisher
Mar 03, 2025

10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey

Mar 03, 2025
pulisher
Mar 02, 2025

Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter

Mar 02, 2025
pulisher
Mar 01, 2025

Long Term Trading Analysis for (RVMD) - Stock Traders Daily

Mar 01, 2025
pulisher
Mar 01, 2025

Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com

Feb 28, 2025
pulisher
Feb 27, 2025

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com

Feb 27, 2025

Revolution Medicines Inc Azioni (RVMD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):